Ownership and insider activity for Niagen Bioscience Inc (NAGE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredi...
Price
| Price | $3.00 |
| Market Cap | $239M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-30 | Lopez Carlos Luis | A-Award | 2,314 | $6K |
| 2026-06-30 | Pamir Ozan | A-Award | 4,255 | $12K |
| 2026-06-30 | Fried Robert N | A-Award | 1,106 | $3K |
| 2026-06-24 | YU Wing Tak Wendy | A-Award | 31,746 | $110K |
| 2026-06-24 | Ng Wang Yu Gary | A-Award | 31,746 | $110K |
| 2026-06-24 | Cohen Ann | A-Award | 31,746 | $110K |
| 2026-06-24 | Patrick Kristin | A-Award | 31,746 | $110K |
| 2026-06-24 | Shahbazi Hamed | A-Award | 31,746 | $110K |
| 2026-06-24 | Rubin Steven D | A-Award | 31,746 | $110K |
| 2026-06-24 | Jaksch Frank L Jr | A-Award | 31,746 | $110K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.6M | $45.4M | $22.4M | $18.6M | $16.5M | $28.0M | $20.3M | $27.2M | $44.5M | $64.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $5.9M | $5.3M | $4.4M | $2.2M | $2.7M | $5.2M | $8.5M | $5.2M | $7.8M | $9.7M |
| Inventory | $7.9M | $5.8M | $8.2M | $11.5M | $11.7M | $13.6M | $14.7M | $14.5M | $9.2M | $20.4M |
| Total Current Assets | $15.7M | $57.2M | $36.5M | $33.5M | $32.2M | $48.9M | $46.6M | $49.5M | $64.1M | $96.8M |
| Property, Plant & Equipment | $1.8M | $2.9M | $3.6M | $4.7M | $4.4M | $7.4M | $6.3M | $4.5M | $3.4M | $3.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $486000 | $1.7M | $1.5M | $1.3M | $1.1M | $857000 | $671000 | $510000 | $359000 | $5.7M |
| Total Assets | $19.8M | $62.7M | $42.2M | $40.2M | $38.4M | $57.8M | $54.1M | $55.0M | $68.3M | $106.4M |
| Accounts Payable | $6.0M | $3.7M | $9.5M | $9.6M | $9.4M | $10.4M | $9.7M | $10.2M | $8.5M | $10.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.0M |
| Total Current Liabilities | $8.9M | $8.1M | $14.4M | $15.1M | $16.5M | $17.6M | $17.9M | $20.6M | $17.9M | $19.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $9.8M | $8.9M | $15.1M | $19.8M | $21.9M | $26.1M | $25.4M | $26.5M | $22.2M | $29.9M |
| Retained Earnings | -$45.2M | -$56.6M | -$89.8M | -$121.9M | -$141.8M | -$169.0M | -$185.5M | -$190.5M | -$181.9M | -$164.5M |
| Total Equity | $10.0M | $53.8M | $27.2M | $20.4M | $16.4M | $31.7M | $28.7M | $28.5M | $46.1M | $76.5M |
| Total Debt | $599050 | $506000 | $310000 | $1.7M | $1.6M | $4.7M | $4.3M | $3.3M | $2.7M | $2.8M |
| Net Debt | -$1.0M | -$44.9M | -$22.1M | -$16.9M | -$14.9M | -$23.3M | -$16.0M | -$23.9M | -$41.9M | -$62.0M |
| Working Capital | $6.9M | $49.1M | $22.1M | $18.5M | $15.7M | $31.3M | $28.7M | $28.9M | $46.2M | $76.9M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 6.50 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 10.48 |
Profitability
| Return on Equity | 20.50% |
| Return on Invested Capital | 8.75% |
| Return on Assets | 15.00% |
| Gross Margin | 64.24% |
| Operating Margin | 6.67% |
| Net Margin | 12.39% |
Related companies: AKBA · CRVS · KALV · KROS · OLMA · PRTA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of NAGE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks